Finally, a recent study reported a novel inhibitor of Fut8 that could inhibit the malignance of CRC cells; therefore, we could assume that novel agonists of Fut2 may also be developed for Fut2-deficiency-induced intestinal disorders. This evidence concerns the gene FUT2 and colorectal carcinoma.